- Home
- TXMD vs LSTA Comparison
TXMD vs LSTA Comparison
Compare TXMD & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TXMD | LSTA |
|---|---|---|
| Founded | 2008 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Misc Health and Biotechnology Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.4M | 28.9M |
| IPO Year | 2012 | 2000 |
Fundamental Metrics
Financial Performance| Metric | TXMD | LSTA |
|---|---|---|
| Price | $2.07 | $1.06 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 17.5K | ★ 121.5K |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 73.68 | 20.42 |
| EPS | ★ 0.01 | N/A |
| Revenue | $1,761,000.00 | ★ $35,283,868.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $209.00 | ★ N/A |
| Revenue Growth | 35.25 | ★ 56.90 |
| 52 Week Low | $0.99 | $0.99 |
| 52 Week High | $2.95 | $5.07 |
Technical Indicators
Market Signals| Indicator | TXMD | LSTA |
|---|---|---|
| Relative Strength Index (RSI) | 55.49 | 19.37 |
| Support Level | $2.07 | N/A |
| Resistance Level | $2.13 | $2.19 |
| Average True Range (ATR) | 0.06 | 0.20 |
| MACD | 0.00 | -0.08 |
| Stochastic Oscillator | 71.11 | 3.23 |
Price Performance
Historical ComparisonAbout TXMD TherapeuticsMD Inc.
TherapeuticsMD Inc is a pharmaceutical royalty company that owns and manages intellectual property, including trademarks and product rights, which are licensed to third-party pharmaceutical companies. The company generates revenue mainly through royalties and milestone payments from licensed products, including IMVEXXY, BIJUVA, and ANNOVERA, and does not directly manufacture or market pharmaceutical products.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The company has one operating segment, the research and development of its investigational drug product.